Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 11/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.51 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.46 |
| ▸ | F12 | P00748 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6159181 | 0.92 | ADRA2A (0.58) | PTGIRADRA2AADRA2BADRA2CGPR65 | |
| SCHEMBL6159085 | 0.88 | ADRA2A (0.58) | PTGIRADRA2AADRA2BADRA2CGPR65 | |
| Hydrochloric Acid SCHEMBL6159956 | 0.87 | ADRA2A (0.56) | PTGIRADRA2AADRA2BADRA2CGPR65 | |
| SCHEMBL6159441 | 0.87 | PTGIR (0.53) | PTGIRADRA2AADRA2BADRA2CGPR65 | |
| SCHEMBL6163238 | 0.86 | ADRA2A (0.56) | PTGIRADRA2AADRA2BADRA2CAOC3 | |
| Hydrochloric Acid SCHEMBL6159099 | 0.85 | ADRA2A (0.55) | PTGIRADRA2AADRA2BADRA2CAOC3 | |
| SCHEMBL4759817 | 0.85 | ADRA2A (0.54) | PTGIRADRA2AADRA2BADRA2CGPR65 | |
| Hydrochloric Acid SCHEMBL6161690 | 0.84 | ADRA2A (0.53) | PTGIRADRA2AADRA2BADRA2CGPR65 | |
| SCHEMBL6159081 | 0.83 | ADRA2A (0.69) | PTGIRADRA2AADRA2BADRA2CGPR65 | |
| Hydrochloric Acid SCHEMBL6159371 | 0.82 | ADRA2A (0.68) | PTGIRADRA2AADRA2BADRA2CGPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339694-B1 | SUBSTITUTED 2-PHENYLAMINOIMIDAZOLINE PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-09-21 | — | — | EP | disclosed |
| EP-1339694-A1 | SUBSTITUTED 2-PHENYLAMINOIMIDAZOLINE PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-03 | — | — | EP | disclosed |
| US-20020091147-A1 | SUBSTITUTED-PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | SYNTEX (U.S.A.) LLC | 2002-07-11 | — | — | US | disclosed |
| US-6417186-B1 | TREATING PAIN, URINARY TRACT INFECTIONS, INFLAMMATION, RESPIRATORY DISEASE STATES FROM ALLERGIES OR ASTHMA, EDEMA FORMATION OR HYPOTENSIVE VASCULAR DISEASES. | SYNTEX (U.S.A.) LLC | 2002-07-09 | — | — | US | disclosed |
| WO-2002040453-A1 | SUBSTITUTED 2-PHENYLAMINOIMIDAZOLINE PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091147-A1 | SUBSTITUTED-PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | PTGER1, FFAR1, BDKRB1 | PTGIR 26/4885ADRA2A 50/4885ADRA2B 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.